G-CSF Treatment for Amyotrophic Lateral Sclerosis
Author Information
Author(s): Duning Thomas, Schiffbauer Hagen, Warnecke Tobias, Mohammadi Siawoosh, Floel Agnes, Kolpatzik Katja, Kugel Harald, Schneider Armin, Knecht Stefan, Deppe Michael, Schäbitz Wolf Rüdiger
Primary Institution: Department of Neurology, University Hospital Muenster, Muenster, Germany
Hypothesis
Is G-CSF treatment feasible for patients with amyotrophic lateral sclerosis (ALS)?
Conclusion
G-CSF treatment in ALS patients is feasible and may help modulate microstructural neural damage.
Supporting Evidence
- G-CSF was well tolerated by all patients who received it.
- No significant differences were found in clinical tests between G-CSF and placebo groups.
- DTI analysis showed significant reductions in fractional anisotropy in ALS patients compared to controls.
- Placebo-treated patients showed a greater decline in brain structure over time compared to those treated with G-CSF.
Takeaway
This study tested a medicine called G-CSF to see if it could help people with ALS. It seems to be safe and might help protect the brain, but more research is needed.
Methodology
Ten ALS patients were randomly assigned to receive either G-CSF or placebo in a double-blind trial, with assessments over 100 days.
Potential Biases
Potential bias due to the small number of participants and the nature of the trial.
Limitations
The small sample size limits the ability to draw definitive conclusions.
Participant Demographics
Median age 58 years; 6 men and 4 women.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website